Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more
Lidds AB (LIDDS) - Net Assets
Latest net assets as of September 2025: Skr1.49 Million SEK
Based on the latest financial reports, Lidds AB (LIDDS) has net assets worth Skr1.49 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.98 Million) and total liabilities (Skr491.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.49 Million |
| % of Total Assets | 75.24% |
| Annual Growth Rate | -14.93% |
| 5-Year Change | -85.57% |
| 10-Year Change | -93.81% |
| Growth Volatility | 32.72 |
Lidds AB - Net Assets Trend (2010–2024)
This chart illustrates how Lidds AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lidds AB (2010–2024)
The table below shows the annual net assets of Lidds AB from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr6.18 Million | -55.54% |
| 2023-12-31 | Skr13.90 Million | -9.45% |
| 2022-12-31 | Skr15.35 Million | -68.36% |
| 2021-12-31 | Skr48.51 Million | +13.32% |
| 2020-12-31 | Skr42.81 Million | -71.86% |
| 2019-12-31 | Skr152.13 Million | -4.03% |
| 2018-12-31 | Skr158.52 Million | +24.57% |
| 2017-12-31 | Skr127.25 Million | +13.09% |
| 2016-12-31 | Skr112.52 Million | +12.78% |
| 2015-12-31 | Skr99.77 Million | +3.53% |
| 2014-12-31 | Skr96.37 Million | +28.14% |
| 2013-12-31 | Skr75.21 Million | +9.57% |
| 2012-12-31 | Skr68.64 Million | -5.13% |
| 2011-12-31 | Skr72.35 Million | +21.66% |
| 2010-12-31 | Skr59.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lidds AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 280769800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr7.23 Million | 117.06% |
| Other Components | Skr3.63 Million | 58.73% |
| Total Equity | Skr6.18 Million | 100.00% |
Lidds AB Competitors by Market Cap
The table below lists competitors of Lidds AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SKANSKA -B- - Dusseldorf Stock Exchang
DU:SKNB
|
$225.97K |
|
Generation Income Properties Inc Warrant
NASDAQ:GIPRW
|
$225.97K |
|
KOPPERS HLDGS
BE:KO9
|
$226.08K |
|
C WorldWide Stabile Aktier KL A
CO:CWISAKTKLA
|
$226.11K |
|
Sprott Physical Silver
TO:PSLV
|
$225.91K |
|
Latitude Tree Holdings Bhd
KLSE:7006
|
$225.77K |
|
WaterBridge Infrastructure LLC
NYSE:WBI
|
$225.70K |
|
Jyske In Fjernøsten Akt SRI KL
CO:JYIFJASRIKL
|
$225.65K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lidds AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,899,000 to 6,179,000, a change of -7,720,000 (-55.5%).
- Net loss of 5,938,000 reduced equity.
- Other factors decreased equity by 1,782,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-5.94 Million | -96.1% |
| Other Changes | Skr-1.78 Million | -28.84% |
| Total Change | Skr- | -55.54% |
Book Value vs Market Value Analysis
This analysis compares Lidds AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.54x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.54x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | Skr5.41 | Skr0.02 | x |
| 2011-12-31 | Skr7.23 | Skr0.02 | x |
| 2012-12-31 | Skr6.86 | Skr0.02 | x |
| 2013-12-31 | Skr7.16 | Skr0.02 | x |
| 2014-12-31 | Skr6.78 | Skr0.02 | x |
| 2015-12-31 | Skr6.68 | Skr0.02 | x |
| 2016-12-31 | Skr5.92 | Skr0.02 | x |
| 2017-12-31 | Skr6.02 | Skr0.02 | x |
| 2018-12-31 | Skr6.58 | Skr0.02 | x |
| 2019-12-31 | Skr5.96 | Skr0.02 | x |
| 2020-12-31 | Skr1.48 | Skr0.02 | x |
| 2021-12-31 | Skr1.41 | Skr0.02 | x |
| 2022-12-31 | Skr0.45 | Skr0.02 | x |
| 2023-12-31 | Skr0.22 | Skr0.02 | x |
| 2024-12-31 | Skr0.05 | Skr0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lidds AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -96.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18556.25%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-96.10%) is below the historical average (-56.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -3.15% | 0.00% | 0.00x | 1.02x | Skr-7.82 Million |
| 2011 | -4.81% | 0.00% | 0.00x | 1.02x | Skr-10.72 Million |
| 2012 | -5.41% | -28822.11% | 0.00x | 1.05x | Skr-10.58 Million |
| 2013 | -5.17% | -50869.62% | 0.00x | 1.02x | Skr-11.41 Million |
| 2014 | -7.33% | 0.00% | 0.00x | 1.02x | Skr-16.70 Million |
| 2015 | -7.83% | 0.00% | 0.00x | 1.03x | Skr-17.79 Million |
| 2016 | -5.90% | 0.00% | 0.00x | 1.08x | Skr-17.89 Million |
| 2017 | -5.24% | -648.44% | 0.01x | 1.03x | Skr-19.39 Million |
| 2018 | -2.36% | -48.33% | 0.05x | 1.03x | Skr-19.60 Million |
| 2019 | -15.67% | 0.00% | 0.00x | 1.04x | Skr-39.05 Million |
| 2020 | -75.53% | -9372.17% | 0.01x | 1.27x | Skr-36.61 Million |
| 2021 | -76.83% | -1048.68% | 0.06x | 1.15x | Skr-42.12 Million |
| 2022 | -240.15% | -1952.33% | 0.07x | 1.69x | Skr-38.39 Million |
| 2023 | -289.27% | 0.00% | -0.01x | 1.27x | Skr-41.60 Million |
| 2024 | -96.10% | -18556.25% | 0.00x | 1.32x | Skr-6.56 Million |
Industry Comparison
This section compares Lidds AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lidds AB (LIDDS) | Skr1.49 Million | -3.15% | 0.33x | $225.92K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |